RXRX$4.64
$4.6697
Chart
Performance
Key Stats
AI RXRX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldRecursion Pharmaceuticals shows strong thematic potential in drug discovery and a generally healthy balance sheet, but faces significant profitability challenges and mixed technical signals. The current valuation is not supported by trailing earnings. Investors should monitor progress in clinical trials and pathways to profitability.
Thematic
Recursion Pharmaceuticals is positioned within the rapidly advancing field of AI-driven drug discovery, a significant secular growth trend. Its integrated approach to decoding biology and chemistry offers a compelling thematic narrative.
Fundamental
Recursion Pharmaceuticals demonstrates strong cash reserves and a growing revenue stream, but exhibits significant net losses and negative free cash flow, reflecting its clinical-stage nature. The valuation metrics are not yet supported by profitability.
Technical
The stock shows mixed technical signals. While the 1-day and 4-hour charts suggest some bullish momentum and trading above key moving averages, shorter-term charts indicate a neutral to slightly bearish sentiment with several 'Sell' signals from moving averages and oscillators.
| Factor | Score |
|---|---|
| AI in Drug Discovery | 90 |
| Biotechnology Innovation | 70 |
| Strategic Partnerships | 80 |
| Market Adoption of Technology | 65 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 75 |
| Balance Sheet Health | 85 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis (1 Day) | 80 |
| Momentum (1 Day) | 70 |
| Short-term Indicators (1 Hour) | 45 |
| Oscillators (1 Hour) | 60 |
| Support/Resistance (1 Day) | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive EPS Surprise History
Recursion Pharmaceuticals (RXRX) has a history of beating earnings estimates, with 7 out of the last 12 reported quarters showing a positive EPS surprise. This suggests a tendency for the company to perform better than anticipated at the earnings level.
Potential Value in Price-to-Sales
While the current Price-to-Sales (P/S) ratio is high at 61.4, historical data shows a significant decrease from previous periods (e.g., 731.0 in 2021), indicating potential normalization or undervaluation if revenue grows substantially.
Bearish Points (7)
Consistent Net Losses
Recursion Pharmaceuticals has reported consistent net losses across all periods, with a TTM net income of -$477.24 million and negative EPS of -$1.8. This indicates a lack of profitability currently.
Extremely High Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio is exceptionally high, standing at 61.4 on a TTM basis and even higher in recent quarters (e.g., 152.3 in Q1 2025). This suggests the company is valued at a significant premium to its current sales, indicating a potential for overvaluation if revenue growth does not materialize rapidly.
Calendar
August 2025
7
Next Earnings Date
H: $-0.29
A: $-0.35
L: $-0.40
H: 22.90M
A: 15.38M
L: 5.00M
Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Seasonals
Price Target
6.67 USD
The 39 analysts offering 1 year price forecasts for RXRX have a max estimate of 10.00 and a min estimate of 4.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Leading provider of GPUs and AI platforms essential for computational tasks in drug discovery, a key partner for Recursion Pharmaceuticals (RXRX). NVIDIA's technology underpins many AI-driven drug discovery efforts, including Recursion's AI supercomputer. [9, 10, 12]
Weight: 95
Direct competitor and pioneer in AI-driven drug discovery, utilizing AI to accelerate drug development from target identification to clinical trials. Exscientia focuses on oncology and inflammatory diseases, similar to Recursion's broad scope in decoding biology. [14]
Weight: 95
Develops physics-based computational platforms and software for molecular modeling and drug discovery, enabling scientists to simulate molecular interactions and design new therapeutic compounds. Schrödinger represents a direct peer in tech-enabled drug design. [9, 12]
Weight: 90
Clinical-stage precision medicine company transforming drug discovery by combining leading-edge computational and experimental approaches. Relay Therapeutics is explicitly mentioned as a primary competitor of Recursion. [6, 12, 16, 33, 34, 36, 45]